← Back to Search

Single Arm for Non-Small Cell Lung Cancer

N/A
Recruiting
Led By Joanna Young, DO
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months after pembrolizumab treatment completion
Awards & highlights

Study Summary

This trial is looking at patients with mNSCLC to see if pembrolizumab reduces the risk of cancer recurring.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months after pembrolizumab treatment completion
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months after pembrolizumab treatment completion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Therapeutic procedure
Secondary outcome measures
Assisted Circulation
Therapeutic procedure
Therapeutic procedure

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment1 Intervention
Biomarkers and ctDNA data generated from patients with metastatic non-small cell lung carcinoma who have completed first line pembrolizumab monotherapy or pembrolizumab-platinum doublet combination therapy, and have, at immunotherapy discontinuation, completed at least 20 of an anticipated 24 months of pembrolizumab.

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,240 Previous Clinical Trials
1,004,137 Total Patients Enrolled
Joanna Young, DOPrincipal InvestigatorWake Forest University Health Sciences
Kathryn Mileham, MDPrincipal InvestigatorWake Forest University Health Sciences

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are we still looking for individuals to participate in this trial?

"As specified on clinicaltrials.gov, this trial is not currently active. The study was initially posted on November 1st, 2020 and updated last on September 29th, 2020. There are 84 other trials searching for patients."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients
2023. "Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05415358.
~47 spots leftby Sep 2035
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top